Moderna reports first positive Phase 3 for mRNA neoantigen therapy in melanoma
Moderna reported its first positive Phase 3 trial for an mRNA-based personalized cancer vaccine (NeoMune) in melanoma, marking a major milestone for neoantigen immunotherapy. The therapy is designed t...